Skip to main content

The Nrf2E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53floxed/floxed/Cdkn2afloxed/floxed mice

Publication ,  Conference
Hamad, S; Montgomery, SA; Simon, JM; Bowman, BM; Spainhower, KB; Murphy, RM; Witkiewicz, A; Fenton, SE; Randell, SH; Hayes, N; Knudsen, E ...
Published in: CANCER RESEARCH
2022

Duke Scholars

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2022

Volume

82

Issue

12

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hamad, S., Montgomery, S. A., Simon, J. M., Bowman, B. M., Spainhower, K. B., Murphy, R. M., … Weissman, B. E. (2022). The Nrf2E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53floxed/floxed/Cdkn2afloxed/floxed mice. In CANCER RESEARCH (Vol. 82).
Hamad, Samera, Stephanie A. Montgomery, Jeremy M. Simon, Brittany M. Bowman, Kyle B. Spainhower, Ryan M. Murphy, Agnieszka Witkiewicz, et al. “The Nrf2E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53floxed/floxed/Cdkn2afloxed/floxed mice.” In CANCER RESEARCH, Vol. 82, 2022.
Hamad S, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Witkiewicz A, Fenton SE, Randell SH, Hayes N, Knudsen E, Oliver TG, Major B, Weissman BE. The Nrf2E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53floxed/floxed/Cdkn2afloxed/floxed mice. CANCER RESEARCH. 2022.

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2022

Volume

82

Issue

12

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis